

## Prior Authorization Request Form for Migraine Acute Treatment Agent

## FAX this completed form to (844) 205-3386

OR Mail requests to: Pharmacy Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720 OR Prior authorization may be completed at https://www.covermymeds.com/main/prior-authorization-forms/

| I. PROVIDER INFORMATION  |   | II. MEMBER INFORMATION  |   |   |  |
|--|---|---|---|---|--|
| Prescriber Name:   |   | Member Name:  |   |   |  |
| Prescriber Specialty:  |   | Identification #:   |   |   |  |
| NPI:   |   | Group #:  |   |   |  |
| Office Contact Name:   |   | Date of Birth:  |   |   |  |
| Fax #:   |   | Medication Allergies:   |   |   |  |
| Phone #:   |   |   |   |   |  |
| III. DRUG INFORMATION (One drug  | grequest per form)  |   |   |   |  |
| Drug name and strength:  | Dosage Interval (sig):  |   | Qty. per Day:   |   |  |
| IV. REQUIRED DOCUMENTION (Det item must be submitted with prior of                           |   |   | ımentation (  | demonstrating evidence for each   |  |
| Specify diagnosis & diagnosis code releva  | int to this request:  |   | Dx/Dx Code: _   |   |  |
| Does the member have a history of contraindication to the prescrib medication?               |   |   | ☐ Yes   |   |  |
|  |   |   | □ No  |   |  |
| Disorder <b>THERAPEUTIC DUPLICATION:</b> Is being titrated to or tapered fron                | nt Agents? Refer to a list of preferred and a d according to the curr n another drug in the s   | non-<br>rent Int<br>same cl   | ass   | end date and dose):eadache Society Classification of Headache orted by national treatment guidelines or |  |
| EXCEEDS QUANTITY LIMITS:   |   |   |   |   |  |
| preventative medication □ Beta-Blocker (e.g. m □ Antidepressant (e.g. □ Anticonvulsant (e.g. | and-Daily-Dose-Limits adache specialist (certification), please indicate a special strong of the following a history of therapeutions from one of the follower operation and the follower operation of the follower operation operation of the follower operation operation operation of the follower operation | c.aspx), perified in pecialising:  c failure owing cle, timolouxine):_acid, div | headache medit:  e, contraindica asses (medica ol):  ralproex): | e supporting dicine but the United Council for  |  |
| ☐ Does the member have a   | a history of therapeution   | c failure   | e, contraindica   | ation or intolerance to standard first-line   |  |
| abortive medications ba  | sed on headache class   | ificatio  | n as recomme  | nded by current consensus guidelines  |  |

|        |  | (such as guidelines from American Academy<br>Headache Society) (medication, start date an  |  |                         |  |  |  |
|--------|--|--|--|-------------------------|--|--|--|
|        | ☐ Has  | documentation of an evaluation for the overus  | se of abortive medications, including opioi  | ds                      |  |  |  |
|        |  | CAL RECORD INFORMATION FOR EACH APPLI  |  |                         |  |  |  |
| _      |  | GEPANT (NURTEC ODT, UBRELVY) FOR ACU   |  |                         |  |  |  |
| Ц      |  | nted history of therapeutic failure, contraindics): (medication, start date and end date): |  |                         |  |  |  |
|        | If curren  | ntly using a different gepant, one of the following  | ng:  |                         |  |  |  |
|        | ☐ Wi   | ll discontinue use of the other gepant prior to s  | starting the requested gepant                |                         |  |  |  |
|        |  | s medical reason for concomitant use of both g<br>atment guidelines                        | repants supported by peer-reviewed litera    | ture or national        |  |  |  |
| REQUE  | ST FOR I   | DITANS (REYVOW):   |  |                         |  |  |  |
|        |  | nted history of therapeutic failure, contraindic<br>l end date):                           |  |                         |  |  |  |
| DEVIIE | CT EOD I   | ERGOT ALKALOIDS (DIHYDROERGOTAMINE   | n.   |                         |  |  |  |
| KEQUE. |  | •  |  | ahantiya madigationa    |  |  |  |
| Ц      | Documented history of therapeutic failure, contraindication or intolerance to standard first-line abortive medications based on headache classification as recommended by current consensus guidelines (such as guidelines from American |  |  |                         |  |  |  |
|        |  | y of Neurology, American Academy of Family F   |  |                         |  |  |  |
|        |  | date):   |  | neuication, start uate  |  |  |  |
|        | anu enu  | uatej  | ·····  |                         |  |  |  |
| REOUE  | ST FOR I   | NON-PREFERRED MIGRAINE ACUTE TREATM  | MENT:  |                         |  |  |  |
|        | For trip   |  |  |                         |  |  |  |
| _      | _  | cumented history of therapeutic failure, contra  | aindication or intolerance to preferred trip | ntans (medication start |  |  |  |
|        |  | te and end date):  |  |                         |  |  |  |
| _      |  |  |  |                         |  |  |  |
| Ш      |  | ther non-preferred Migraine Acute Treatment  |  |                         |  |  |  |
|        | Documented history of therapeutic failure, contraindication or intolerance to preferred Migraine Acute Treatment approved or medically accepted for the member's diagnosis (medication, start date and end date):                        |  |  |                         |  |  |  |
| DENIEW | AL REQ   | IFCTC.   |  |                         |  |  |  |
| KENEW  | •  | has experienced an improvement in headache   | angin cumptome or duration                   |                         |  |  |  |
|        | Member   | has experienced an improvement in headache   | e pain, symptoms of duration                 |                         |  |  |  |
| IV. AI | DITIO  | IAL RATIONALE FOR REQUEST / PERTI  | NENT CLINICAL INFORMATION :                  |                         |  |  |  |
|        |  | · · · · · · · · · · · · · · · · · · ·  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  |  |  |                         |  |  |  |
|        |  | nical information to support the request on  | Provider Signature:                          | Date:                   |  |  |  |
| the ba | sis of me  | dical necessity must be submitted.   |  |                         |  |  |  |
| 31     |  |  |  |                         |  |  |  |

Pharmacy Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)